GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AegirBio AB (GREY:AEGBF) » Definitions » EV-to-EBIT

AegirBio AB (AegirBio AB) EV-to-EBIT : -2.02 (As of May. 24, 2024)


View and export this data going back to 2023. Start your Free Trial

What is AegirBio AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AegirBio AB's Enterprise Value is $5.18 Mil. AegirBio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.56 Mil. Therefore, AegirBio AB's EV-to-EBIT for today is -2.02.

The historical rank and industry rank for AegirBio AB's EV-to-EBIT or its related term are showing as below:

AEGBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -169.58   Med: -1.63   Max: 0.03
Current: -1.99

During the past 4 years, the highest EV-to-EBIT of AegirBio AB was 0.03. The lowest was -169.58. And the median was -1.63.

AEGBF's EV-to-EBIT is ranked worse than
100% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 20.155 vs AEGBF: -1.99

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AegirBio AB's Enterprise Value for the quarter that ended in Mar. 2024 was $6.93 Mil. AegirBio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.56 Mil. AegirBio AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -36.94%.


AegirBio AB EV-to-EBIT Historical Data

The historical data trend for AegirBio AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AegirBio AB EV-to-EBIT Chart

AegirBio AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
- -24.05 -10.82 -0.10

AegirBio AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.11 -0.09 -0.12 -2.14

Competitive Comparison of AegirBio AB's EV-to-EBIT

For the Medical Devices subindustry, AegirBio AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AegirBio AB's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AegirBio AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AegirBio AB's EV-to-EBIT falls into.



AegirBio AB EV-to-EBIT Calculation

AegirBio AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.177/-2.561
=-2.02

AegirBio AB's current Enterprise Value is $5.18 Mil.
AegirBio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AegirBio AB  (GREY:AEGBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AegirBio AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-2.561/6.932459
=-36.94 %

AegirBio AB's Enterprise Value for the quarter that ended in Mar. 2024 was $6.93 Mil.
AegirBio AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AegirBio AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AegirBio AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


AegirBio AB (AegirBio AB) Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.

AegirBio AB (AegirBio AB) Headlines

No Headlines